Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That's why I'll wait. If I buy now and they dilute, my shares go down in value. They can dilute up to 1.2 billion. Until they lower the A/S, R/S or remove the CEO I'll wait.
I'm trying to see the positives in this company, but damn does this CEO sell shares. I believe we need this in the future, but this company needs a different CEO.
Yikes
During the three months ended December 31, 2020, the Company incurred $22,616,960 of operating expenses compared to $1,083,131 of operating expenses during the three months ended December 31, 2019. Overall, the increase in operating expense was due to the fact that the Company issued 27,490,000 common shares for consulting services with a fair value of $21,065,200 in fiscal 2020 compared with the issuance of 5,560,000 common shares with a fair value of $233,520 for consulting services during the three months ended December 31, 2019. Of the remaining operating expenses not related to share-based compensation of $1,503,536 the expenditures were higher than the prior period amount of $849,611 due to an increase in general and administrative expense as the overall level of day-to-day operating costs increased including increases in payroll and benefits expense as the Company required more staffing compared to prior year.
In addition to operating expenses, the Company incurred other income and expense of $5,430,909 during the three months ended December 31, 2020 compared to $1,864,934 during the three months ended December 31, 2019. The increase was due to a higher loss relating to the change in fair value of the derivative liability of $6,244,285 compared to $876,960 during the three months ended December 31, 2019 due to the fact that the Company experienced a larger volatility or spread in its share price at December 31, 2020 which resulted in a larger value attributed to the conversion feature of the Company’s outstanding convertible debentures for the period. In addition, the Company recorded a gain on the settlement of debt of $1,850,178 for the three months ended December 31, 2020 compared to $127,863 during the three months ended December 31, 2019 due in large part to the fact that the Company was successful in raising financing proceeds from the issuance of common shares which resulted in the Company repaying some outstanding convertible debentures resulting in the reversal of the fair value of the derivative liability. Overall, the Company recorded accretion and interest expense of $837,953 during the three months ended December 31, 2020 compared to $1,119,583 during the three months ended December 31, 2019 and the decrease was due to the repayment of various convertible debentures resulting in lower accretion and interest costs incurred during the current period. As part of the repayment of convertible debentures during the period, the Company incurred financing and early payment penalty costs of $190,980.
May is around the corner. I would think the 1's are out of the picture after this week.
Thanks
Just for fun. I'll follow you on this one. I bought 11,330 shares. GL to both of us.
I have seen it many times as well. Interesting company, I'll definitely keep an eye on it throughout the years.
I was thinking the same thing. A/S is 1.2 billion and the O/S as of 04/09/2021 is 555,976,046. The O/S has increased 21 million since March 2021. Maybe once the building is built they will stop diluting. Maybe the share offering at $1.65 will hold them over, but not a good sign.
Thanks for the charts on CTXR for the past couple of days. How long have you been doing this? I remember in 2009 you were doing a lot of videos.
That makes no sense. What's the current O/S? Anybody call the TA 1 800 990 1135 to verify?
When is the reverse split? Anybody have an updated O/S? last I checked 2 years ago was 1.9 billion.
I'm in, bought some today. General aviation has taken off since COVID.
Yikes, that's a long time. Thanks for the response. I'll keep it on my watch list for now.
I'm not sure who Dawson James is, but they have a 8$ price tag. I think it will be worth 5$ or more in April when/if Mino-Lok is approved.
https://dawsonjames.com/wp-content/uploads/2021/02/CTXR.2.18.21.pdf
Why buy this company? There is no volume at all. How do you get rid of your shares if you want to sell?
Have you actually looked at the management of this company? Do you see how much money the CEO put up? Did you see how they have not sold a share? I have never seen it in any company OTC or not.
Why is this SPAC trading near $10.00? I might buy just for that factor. Wheels up is a great company. Smart man to start out with a work horse, King Air 350's.
I agree. Instead they hired the AMCI guy who is also doing another SPAC. I don't agree with that.
Loaded more at 1.51, I'll be buying more if it drops. Can't wait for April Mino-Lok
That was painful, but bought more for the long term.
I think a lot of companies will be using ADN. FCEL is using ADN's technology and I'm hoping DCRB is or will in the future.
I can't believe they have over 50 patents. Most companies are lucky to have 3 or less.
50 international patents; 15 years of research leading to the development of intellectual property including the next generation of materials for high-temperature polymer electrolyte membrane (HT-PEM) fuel cell technology from Advent’s selection in the L’Innovator program that promise higher power and lifetime at lower cost; a collaboration, funded by an Advanced Research Projects Agency–Energy (“ARPA-E”) OPEN award, to continue development of next-generation HT-PEM fuel cell technology; leveraging HT-PEM for deploying liquid hydrogen carriers such as dimethyl ether (DME) in fuel cells through funding by the Office of Energy Efficiency and Renewable Energy (EERE) of the DoE; and introducing advanced low cost water electrolysis for the production of hydrogen via the conclusion of a Department of Energy (“DoE”) HydroGen Program. All these achievements enable Advent to develop fuel cells ideally suited for heavy-duty automotive and aviation applications
Thanks, I bought more at $15.11
I bought heavy in ADN and started buying some DCRB. Two totally different companies, but both in the hydrogen market. Anybody know more on the merger?
Added more today. I like how their technology can be applied to many outlets.
A/S is 100,000,000
O/S is 9,061,136 as of November 2020
https://www.sec.gov/Archives/edgar/data/1744494/000114036118043271/s002355x9_424b4.htm
I'm sure that will change when they merge, but good to know. What's the A/S?
Something is brewing again. Maybe it will trading at $3.00 plus where it belongs.
What an interesting SPAC play. Hydrogen is the future
Averaged up and bought 14.30 and more buy orders under 14
Page 13 is what caught my attention. https://www.sec.gov/Archives/edgar/data/1818355/000119312520311998/d54063d425.htm
Big F%$# Tities why not
Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company developing and commercializing critical care drug products, announced that it has signed an exclusive agreement with Novellus Therapeutics Limited ("Novellus") to license iPSC-derived mesenchymal stem cells (iMSCs), and has created a new subsidiary, NoveCite, that will be focused on developing cellular therapies.
NoveCite has a worldwide exclusive license from Novellus, an engineered cellular medicines company, to develop and commercialize NoveCite mesenchymal stem cells ("NC-iMSCs") to treat acute respiratory conditions with a near term focus on Acute Respiratory Distress Syndrome ("ARDS") associated with COVID-19. Several cell therapy companies using donor-derived MSC therapies in treating ARDS have demonstrated that MSCs reduce inflammation, enhance clearance of pathogens and stimulate tissue repair in the lungs. Almost all these positive results are from early clinical trials or under the emergency authorization program.
NC-iMSCs are the next generation mesenchymal stem cell therapy. They are believed to be differentiated and superior to donor-derived MSCs. Human donor-derived MSCs are sourced from human bone marrow, adipose tissue, placenta, umbilical tissue, etc. and have significant challenges (e.g., variable donor and tissue sources, limited supply, low potency, inefficient and expensive manufacturing). iMSCs overcome these challenges because they:
Are more potent and secrete exponentially higher levels of immunomodulatory proteins;
Have practically unlimited supply for high doses and repeat doses;
Are from a single donor and clonal so they are economically produced at scale with consistent quality and potency, as well as being footprint free (compared to viral reprogramming methods); and,
Have significantly higher expansion capability.
Globally, there are 3 million cases of ARDS every year out of which approximately 200,000 cases are in the United States. The COVID-19 pandemic has added significantly to the number of ARDS cases. Once the COVID patients advance to ARDS, they are put on mechanical ventilators. Death rate among patients on ventilators can be as high as 50% depending on associated co-morbidities. There are no approved treatments for ARDS, and the current standard of care only attempts to provide symptomatic relief.
"NoveCite iMSCs have the potential to be a breakthrough in the field of cellular therapy for acute respiratory conditions because of the high potency seen in Novellus' pre-clinical studies, and because iMSCs are iPSC-derived, and therefore overcome the manufacturing challenges associated with donor derived cells," said Myron Holubiak, Chief Executive Officer of Citius.
"We are excited to be part of this effort because of the promise to save lives and reduce long term sequelae in patients with devastating respiratory diseases such as ARDS caused by COVID-19," said Dr. Matthew Angel, Chief Science Officer of Novellus. "Our iMSC technology has multimodal immunomodulatory mechanisms of action that make it potentially promising therapy to treat acute respiratory diseases."
ARR also rebalanced the balance sheet. They went from a leverage ratio of 9 to 1 in the last couple of months. New book value is 11ish. A lot safer now
TK CEO stated that TNK has a better QRT 1 then Qrt 4 last year and on track for an even better QRT 2. $$$
7 months of collecting dividends (.17 a month), not sure what the problem is
ARR recovered well from the dividend drop
Why would they dump? June is the magic month?
Bought TNK today and more TK, I think the coronavirus is overplayed.
That and the coronavirus. I added a position in TK Friday for the first time. I'll add TNK if it stays this low. It would be nice to see dividends again, but I also like the direction of paying off debt.